The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Highlights on myelofibrosis from ASH
Claire Harrison
• 21 Dec 2018
Claire Harrison, MD, FRCP, FRCPath, of the Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares an overview of key updates in treatment for myelofibrosis, including ongoing clinical trials, novel treatment combinations, and developments from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
